OncoSec Medical Inc (ONCS)

1.27
NASDAQ : Health Care
Prev Close 1.25
Day Low/High 1.24 / 1.28
52 Wk Low/High 1.03 / 3.49
Avg Volume 471.00K
Exchange NASDAQ
Shares Outstanding 20.87M
Market Cap 26.09M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

OncoSec Granted FDA Fast Track Designation For ImmunoPulse® IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab

OncoSec Granted FDA Fast Track Designation For ImmunoPulse® IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab

Provides Opportunities for Upcoming Phase 2b PISCES Clinical Trial and Future Clinical Development

OncoSec To Host KOL Event Focused On New ASCO-SITC Melanoma Data And Clinical Strategy On Tuesday, February 28 In New York City

OncoSec To Host KOL Event Focused On New ASCO-SITC Melanoma Data And Clinical Strategy On Tuesday, February 28 In New York City

Key Opinion Leaders in Melanoma and Company Representatives to Discuss Unmet Needs in Immunotherapy

OncoSec To Present At NobleCon13

OncoSec To Present At NobleCon13

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

- OncoSec is Executing on a Melanoma Registration-Directed Clinical Program with Immunopulse® IL-12 and Anti-PD-1 Therapy

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

Company to Host Investor and Analyst Day on November 17, 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

Company to Host Investor and Analyst Day on November 17, 2016

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

Here's a technical look at how to trade five stocks that are ready to break out and trade higher from current levels.

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

ImmunoPulse™ IL-12 May Lead to Increased CD8+ T-Cell Infiltration in Patients with Squamous Cell Carcinoma of the Head and Neck, Suggesting That It May Prime Responses to Anti-PD-1 Blockade

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

The combination of OncoSec's ImmunoPulse™ IL-12 and pembrolizumab is the first clinical trial to use this assay to select specific patients, who are unlikely to respond to monotherapy with anti-PD-1 agents